National Planning Corp boosted its position in shares of Celgene Corp. (NASDAQ:CELG) by 19.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,911 shares of the biopharmaceutical company’s stock after buying an additional 1,899 shares during the period. National Planning Corp’s holdings in Celgene Corp. were worth $1,361,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Carmignac Gestion boosted its position in shares of Celgene Corp. by 28.1% in the second quarter. Carmignac Gestion now owns 9,708,359 shares of the biopharmaceutical company’s stock worth $957,535,000 after buying an additional 2,127,659 shares during the period. Wellington Management Group LLP boosted its position in shares of Celgene Corp. by 29.3% in the first quarter. Wellington Management Group LLP now owns 9,105,975 shares of the biopharmaceutical company’s stock worth $911,417,000 after buying an additional 2,062,585 shares during the period. Orbis Allan Gray Ltd acquired a new position in shares of Celgene Corp. during the first quarter worth $119,631,000. Bank of Montreal Can acquired a new position in shares of Celgene Corp. during the second quarter worth $117,274,000. Finally, Emerald Acquisition Ltd. acquired a new position in shares of Celgene Corp. during the second quarter worth $59,003,000. Hedge funds and other institutional investors own 77.75% of the company’s stock.

Celgene Corp. (NASDAQ:CELG) traded up 1.03% on Wednesday, reaching $109.54. 672,975 shares of the company’s stock were exchanged. The firm has a market capitalization of $84.91 billion, a price-to-earnings ratio of 46.30 and a beta of 1.31. Celgene Corp. has a 12 month low of $93.05 and a 12 month high of $128.39. The firm has a 50-day moving average of $110.21 and a 200-day moving average of $105.03.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.05. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. The firm earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. During the same period in the prior year, the firm earned $1.23 EPS. The business’s revenue was up 20.9% on a year-over-year basis. On average, equities analysts expect that Celgene Corp. will post $5.71 earnings per share for the current year.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a research note on Friday, August 5th. BTIG Research raised shares of Celgene Corp. from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $116.14 to $138.00 in a research note on Wednesday, August 3rd. Vetr raised shares of Celgene Corp. from a “sell” rating to a “hold” rating and set a $111.26 price objective for the company in a research note on Monday, August 1st. Stifel Nicolaus reissued a “buy” rating and set a $138.00 price objective on shares of Celgene Corp. in a research note on Tuesday, August 2nd. Finally, Morgan Stanley reissued a “hold” rating and set a $120.00 price objective on shares of Celgene Corp. in a research note on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $138.10.

In other Celgene Corp. news, Director Gilla Kaplan sold 9,710 shares of the stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total value of $1,033,532.40. Following the completion of the sale, the director now directly owns 72,142 shares of the company’s stock, valued at approximately $7,678,794.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $110.00, for a total transaction of $11,000,000.00. Following the completion of the sale, the insider now directly owns 1,022,201 shares of the company’s stock, valued at $112,442,110. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by company insiders.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.